Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fesoterodine fumarate
Drug ID BADD_D00892
Description Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Indications and Usage For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Marketing Status approved
ATC Code G04BD11
DrugBank ID DB06702
KEGG ID D08923
MeSH ID C526675
PubChem ID 9849808
TTD Drug ID D00BLL
NDC Product Code 43598-248; 16262-001; 62559-376; 67877-064; 68382-480; 65977-0093; 65162-369; 65862-767; 70771-1168; 46708-175; 62332-175; 68180-618; 68382-479; 50370-0031; 65862-766; 68180-619; 0069-0242; 0069-0244; 62332-176; 65162-370; 16262-002; 43598-247; 46708-176; 63539-183; 70771-1169; 51407-662; 63539-242; 67877-068; 66005-0035; 71666-005; 51407-661
UNII EOS72165S7
Synonyms fesoterodine | toviaz | fesoterodine fumarate
Chemical Information
Molecular Formula C30H41NO7
CAS Registry Number 286930-03-8
SMILES CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain upper07.01.05.003--
Alanine aminotransferase increased13.03.04.005--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Back pain15.03.04.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry throat22.12.03.005; 07.06.01.005--Not Available
Dyspepsia07.01.02.001--
Dysuria20.02.02.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Gamma-glutamyltransferase increased13.03.04.024--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Insomnia17.15.03.002; 19.02.01.002--
Nausea07.01.07.001--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Palpitations02.11.04.012--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Respiratory disorder22.02.07.002--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Urinary tract obstruction20.08.01.004--
Obstructive airways disorder22.03.01.011--Not Available
The 1th Page    1    Total 1 Pages